tiprankstipranks
Trending News
More News >
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
US Market
Advertisement

Mereo Biopharma Group Plc (MREO) Stock Forecast & Price Target

Compare
659 Followers
See the Price Targets and Ratings of:

MREO Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Mereo
Biopharma Group Plc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MREO Stock 12 Month Forecast

Average Price Target

$7.20
▲(309.09%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Mereo Biopharma Group Plc in the last 3 months. The average price target is $7.20 with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 309.09% change from the last price of $1.76.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,3.316923076923077,3.873846153846154,4.430769230769231,4.987692307692308,5.544615384615385,6.101538461538461,6.658461538461538,7.2153846153846155,7.772307692307693,8.329230769230769,8.886153846153846,9.443076923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,3.1015384615384614,3.443076923076923,3.7846153846153845,4.126153846153846,4.467692307692308,4.809230769230769,5.150769230769231,5.492307692307692,5.833846153846154,6.1753846153846155,6.516923076923077,6.858461538461539,{"y":7.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,2.9323076923076923,3.1046153846153843,3.276923076923077,3.449230769230769,3.6215384615384614,3.793846153846154,3.966153846153846,4.138461538461538,4.310769230769231,4.483076923076923,4.655384615384616,4.827692307692308,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.41,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$7.20Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on MREO
Gil BlumNeedham
Needham
$7$5
Buy
184.09%
Upside
Reiterated
07/10/25
Mereo Biopharma Group Plc: Buy Rating Maintained Amid Challenges and Promising Study Outcomes
BTIG
$6
Buy
240.91%
Upside
Reiterated
07/09/25
Promising Outlook for Mereo Biopharma's Setrusumab Amid Phase 3 Trial Advances and Market Potential
LifeSci Capital Analyst forecast on MREO
Cory Jubinville, PhDLifeSci Capital
LifeSci Capital
$10
Buy
468.18%
Upside
Reiterated
07/09/25
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (NASDAQ: MREO), Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)
J.P. Morgan Analyst forecast on MREO
Priyanka GroverJ.P. Morgan
J.P. Morgan
$7
Buy
297.73%
Upside
Reiterated
07/09/25
J.P. Morgan Keeps Their Buy Rating on Mereo Biopharma Group Plc (MREO)
Leerink Partners Analyst forecast on MREO
Joseph SchwartzLeerink Partners
Leerink Partners
$8
Buy
354.55%
Upside
Reiterated
05/13/25
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Promising Lead Programs and Strong Financial PositionWe continue to believe it is a matter of when (not if) we see positive data and think the second interim is likely to hit (see our deep dive here). Meanwhile, MREO continues to lay the groundwork to prepare for a successful commercial launch in the UK and EU, including engagement with regulatory/HTA bodies and real- world data collection efforts via the SATURN program. Regarding alvelestat, the company remains in discussion with multiple potential partners for the development and commercialization as start-up activities for the planned single and global pivotal Phase 3 study are ongoing.
Goldman Sachs Analyst forecast on MREO
Unknown AnalystGoldman Sachs
Not Ranked
Goldman Sachs
$7
Buy
297.73%
Upside
Initiated
03/27/25
Mereo Biopharma ADRs Rated New Overweight at JPMorgan; PT $7
Cantor Fitzgerald Analyst forecast on MREO
Kristen KluskaCantor Fitzgerald
Cantor Fitzgerald
$7
Buy
297.73%
Upside
Reiterated
03/26/25
Cantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)
Jefferies
$7
Buy
297.73%
Upside
Initiated
12/06/24
Mereo Biopharma Group Plc: Strong Buy Rating Due to Promising Pipeline and Strategic Partnerships
Robert W. Baird Analyst forecast on MREO
Jack AllenRobert W. Baird
Robert W. Baird
$8
Buy
354.55%
Upside
Reiterated
11/12/24
Positive Outlook for Mereo Biopharma Group Plc Amidst Promising Therapeutic Developments and Strong Financial Position
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on MREO
Gil BlumNeedham
Needham
$7$5
Buy
184.09%
Upside
Reiterated
07/10/25
Mereo Biopharma Group Plc: Buy Rating Maintained Amid Challenges and Promising Study Outcomes
BTIG
$6
Buy
240.91%
Upside
Reiterated
07/09/25
Promising Outlook for Mereo Biopharma's Setrusumab Amid Phase 3 Trial Advances and Market Potential
LifeSci Capital Analyst forecast on MREO
Cory Jubinville, PhDLifeSci Capital
LifeSci Capital
$10
Buy
468.18%
Upside
Reiterated
07/09/25
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (NASDAQ: MREO), Amgen (NASDAQ: AMGN) and BeOne Medicines (NASDAQ: ONC)
J.P. Morgan Analyst forecast on MREO
Priyanka GroverJ.P. Morgan
J.P. Morgan
$7
Buy
297.73%
Upside
Reiterated
07/09/25
J.P. Morgan Keeps Their Buy Rating on Mereo Biopharma Group Plc (MREO)
Leerink Partners Analyst forecast on MREO
Joseph SchwartzLeerink Partners
Leerink Partners
$8
Buy
354.55%
Upside
Reiterated
05/13/25
Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Promising Lead Programs and Strong Financial PositionWe continue to believe it is a matter of when (not if) we see positive data and think the second interim is likely to hit (see our deep dive here). Meanwhile, MREO continues to lay the groundwork to prepare for a successful commercial launch in the UK and EU, including engagement with regulatory/HTA bodies and real- world data collection efforts via the SATURN program. Regarding alvelestat, the company remains in discussion with multiple potential partners for the development and commercialization as start-up activities for the planned single and global pivotal Phase 3 study are ongoing.
Goldman Sachs Analyst forecast on MREO
Unknown AnalystGoldman Sachs
Not Ranked
Goldman Sachs
$7
Buy
297.73%
Upside
Initiated
03/27/25
Mereo Biopharma ADRs Rated New Overweight at JPMorgan; PT $7
Cantor Fitzgerald Analyst forecast on MREO
Kristen KluskaCantor Fitzgerald
Cantor Fitzgerald
$7
Buy
297.73%
Upside
Reiterated
03/26/25
Cantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)
Jefferies
$7
Buy
297.73%
Upside
Initiated
12/06/24
Mereo Biopharma Group Plc: Strong Buy Rating Due to Promising Pipeline and Strategic Partnerships
Robert W. Baird Analyst forecast on MREO
Jack AllenRobert W. Baird
Robert W. Baird
$8
Buy
354.55%
Upside
Reiterated
11/12/24
Positive Outlook for Mereo Biopharma Group Plc Amidst Promising Therapeutic Developments and Strong Financial Position
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mereo Biopharma Group Plc

1 Month
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+7.85%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +7.85% per trade.
3 Months
xxx
Success Rate
11/16 ratings generated profit
69%
Average Return
+12.40%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +12.40% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
9/16 ratings generated profit
56%
Average Return
+56.86%
reiterated a buy rating 3 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +56.86% per trade.
2 Years
xxx
Success Rate
12/23 ratings generated profit
52%
Average Return
+93.96%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 52.17% of your transactions generating a profit, with an average return of +93.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MREO Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
13
13
16
10
12
Buy
0
0
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
13
16
11
13
In the current month, MREO has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MREO average Analyst price target in the past 3 months is 7.20.
Each month's total comprises the sum of three months' worth of ratings.

MREO Financial Forecast

No data currently available

MREO Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

MREO Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

MREO Stock Forecast FAQ

What is MREO’s average 12-month price target, according to analysts?
Based on analyst ratings, Mereo Biopharma Group Plc’s 12-month average price target is 7.20.
    What is MREO’s upside potential, based on the analysts’ average price target?
    Mereo Biopharma Group Plc has 309.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MREO a Buy, Sell or Hold?
          Mereo Biopharma Group Plc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Mereo Biopharma Group Plc’s price target?
            The average price target for Mereo Biopharma Group Plc is 7.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $5.00. The average price target represents 309.09% Increase from the current price of $1.76.
              What do analysts say about Mereo Biopharma Group Plc?
              Mereo Biopharma Group Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of MREO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis